Pellitory Allergy Shots: Mediterranean Major Allergen Emerging in the US
Pellitory (Parietaria spp.) allergy shots reduce rhinitis burden in one of the world's longest pollen seasons — February through November in mild climates. Italian SCIT RCTs (Frati et al. 2006) demonstrate efficacy comparable to ragweed immunotherapy, making pellitory the highest-evidence allergen in the rare-weed SCIT category. Par j 2 component testing distinguishes genuine sensitization from pan-allergen co-sensitization before starting shots.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Pellitoryis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Pellitory Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to pellitory — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of pellitory allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of pellitory immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of pellitory extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for pellitory allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing pellitory extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription pellitory immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat pellitory allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Pellitory?
The biology, taxonomy, and clinical fingerprint of Pellitory — the foundation of how SCIT targets it.
Parietaria judaica growing in wall cracks — its preferred urban microhabitat. The plant pollinates nearly continuously from February through November in mild coastal climates.
- Scientific name
- Parietaria judaica / Parietaria officinalis
- Family
- UrticaceaeNettle family
- Type
- Perennial weed pollen
- Native to
- Mediterranean basin (southern Europe, North Africa)
- Allergen proteins
- Par j 1 (nsLTP, major)Par j 2 (nsLTP, major)Par j 3 (profilin, minor)Par j 4 (polcalcin, minor)
- Particle size
- 12–18 μm
- Avoidance difficulty
- Nearly impossible
How Pellitory Allergy Presents
Symptoms by body system — useful for distinguishing Pellitory sensitivity from overlapping allergies and infections.
Respiratory
- Persistent rhinitis lasting most of the year in Mediterranean climates
- Moderate to severe nasal congestion during peak release periods
- Postnasal drip with chronic throat clearing
- Pollen-triggered asthma, particularly with high urban counts
- Worsening of symptoms near wall-growing plant colonies
Ocular
- Intense bilateral conjunctivitis during the long pollen season
- Tearing and photophobia during peak counts
- Periorbital swelling in highly sensitized patients
- Persistent ocular itching that antihistamines inadequately control
Dermal
- Urticaria in highly sensitized individuals during peak pollen periods
- Atopic dermatitis flares correlated with pollen season
- Contact urticaria from direct plant handling (rare)
Systemic
- Fatigue and sleep disruption from near-perennial symptoms
- Reduced quality of life scores comparable to ragweed-sensitized populations
- Asthma exacerbations requiring emergency care during heavy-pollen days
- Cognitive impairment from chronic nasal obstruction
Pellitory is still being missed in California coastal practices. I routinely see patients who've been treated for 'year-round grass allergy' for years — when Par j 2 testing finally shows genuine Parietaria sensitization, the biology of their February-onset rhinitis suddenly makes sense. This is not a European curiosity anymore.
When & Where Pellitory Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: February through May in Southern California; near-continuous February–November in warm coastal climates· Up to 9–10 months of continuous pollen release in Mediterranean-type climates — among the longest seasons of any major aeroallergen
US Exposure Map
1 high-intensity statesExposure intensity by state (text version)
- ME:
- None
- VT:
- None
- NH:
- None
- WA:
- Low
- MT:
- None
- ND:
- None
- MN:
- None
- WI:
- None
- MI:
- None
- NY:
- Low
- MA:
- None
- OR:
- Low
- ID:
- None
- WY:
- None
- SD:
- None
- IA:
- None
- IL:
- None
- IN:
- None
- OH:
- None
- PA:
- None
- NJ:
- Low
- CT:
- None
- RI:
- None
- CA:
- High
- NV:
- Low
- UT:
- None
- CO:
- None
- NE:
- None
- MO:
- None
- KY:
- None
- WV:
- None
- VA:
- Low
- MD:
- Low
- DE:
- None
- AZ:
- Moderate
- NM:
- Low
- KS:
- None
- AR:
- None
- TN:
- None
- NC:
- Low
- SC:
- Low
- OK:
- None
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Moderate
- FL:
- Moderate
- AK:
- None
- HI:
- Moderate
What Pellitory Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Pellitory's major allergens Par j 1 and Par j 2 are non-specific lipid transfer proteins (nsLTPs) that do NOT significantly cross-react with food LTPs (such as Pru p 3 in peach), making them uniquely species-specific markers rather than pan-allergen drivers.
Same Urticaceae family but Par j 1/2 LTPs are not present in Urtica; cross-reactivity is limited to minor pan-allergens only (Stumvoll et al. 2002)
Cross-reactivity via profilin and polcalcin pan-allergens only, not via major species-specific proteins
Pan-allergen cross-reactivity via polcalcin (Par j 4/Pla l 2-equivalent); no major-allergen sharing
Limited cross-reactivity via profilin pan-allergens; Art v 1 and Par j 1 are structurally unrelated
Is SCIT Right for Your Pellitory Allergy?
Answer five questions to see whether pellitory allergy shots are likely to benefit your specific situation.
How severe are your pellitory/weed pollen symptoms during the spring and summer months?
The Pellitory SCIT Protocol
Pellitory SCIT uses a non-standardized Parietaria extract in the US, following standard inhalant allergen build-up and maintenance schedules. In Europe, standardized extracts (Staloral, Alk Phostal) with published SCIT and SLIT dosing are available; US allergists extrapolate from this European evidence.
Gradually increasing concentrations of Parietaria extract, starting at a highly dilute dose and advancing toward the target maintenance dose. Pre-seasonal initiation — beginning at least 12 weeks before the February pollen onset (i.e., in November) — is recommended to reach maintenance-level protection before peak season. A board-certified allergist will titrate based on local reaction size.
Once the target maintenance dose is reached, maintenance injections sustain immunological tolerance. Systemic reactions, when they occur, typically begin within about 30 minutes of an injection; with Curex, trained Curex clinical staff supervise the first injection from each new vial or concentration live in the Virtual Shot Room and confirm a prescribed epinephrine auto-injector on hand. Italian SCIT evidence demonstrates significant symptom-score and medication-use reductions during the maintenance phase (Frati et al. 2006 Curr Med Res Opin).
After completing a 3–5 year SCIT course, many patients maintain reduced symptom burden for years after discontinuation. This lasting immunological effect is one of the primary advantages of immunotherapy over continued pharmacotherapy.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Pellitory SCIT
Pellitory SCIT has the strongest clinical evidence base of any allergen in the rare-weed SCIT category, anchored by Italian RCTs from the Frati and Passali groups with patient populations experiencing genuine Mediterranean-type pollinosis.
- Symptom score reduction (SCIT vs. placebo)65%Frati et al. 2006, Curr Med Res Opin, Italian multicenter RCT
- Medication use reduction after 3-year SCIT60%Passali et al. 2010, SLIT/SCIT comparative Italian evidence review
- Rhinitis quality of life improvement58%D'Amato et al. 2007, Allergy 62:976–990, Mediterranean cohort data
Italian RCT evidence demonstrates meaningful clinical benefit from Pellitory SCIT in Mediterranean-sensitized populations; US-specific RCT data are lacking because Parietaria has historically been considered a European problem. As the plant expands into coastal California, extrapolation from European studies with standardized extract is the best available evidence basis.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Pellitory SCIT Side Effects
Pellitory SCIT side effects follow the general inhalant allergen pattern documented in the AAAAI Practice Parameters (Cox 2011 JACI). With Curex, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector is confirmed on hand before the first injection.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Wheal and flare at injection site; resolves within hours | Rate 30–50% | Mild |
Injection-site itching | Rate 25–40% | Mild |
Large local reaction (>5 cm) May require dose adjustment; not predictive of systemic reaction | Rate 5–15% | Moderate |
Delayed local swelling Onset 4–8 hours post-injection; self-limited | Rate 5–10% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or ocular flare | Rate 1–5% | Mild |
Generalized urticaria | Rate 0.1–0.5% per injection | Moderate |
Bronchospasm Risk elevated in patients with uncontrolled asthma | Rate <0.1% per injection | Severe |
Anaphylaxis Curex supervises the first injection from each new vial or concentration live in the Virtual Shot Room and confirms a prescribed epinephrine auto-injector on hand | Rate <0.01% per injection | Severe |
SCIT-related fatalities are exceedingly rare in the US under proper protocols. Curex preserves that safety margin at home: a USP <797> sterile-compounded serum, a Virtual Shot Room–supervised the first injection from each new vial or concentration, a prescribed epinephrine auto-injector confirmed on hand, and gradual allergist-overseen escalation. Patients with poorly controlled asthma face higher systemic reaction risk and should have FEV1 assessed before initiating treatment.
SCIT vs Alternatives for Pellitory
Pellitory-allergic patients in the US have four treatment options: SCIT (supported by Italian RCT evidence), at-home SLIT drops, pharmacotherapy, or avoidance — which is impractical given the nearly year-round pollen season.
| Criterion | At-Home SCIT (Curex)Best | SLIT drops/tablets | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | High (RCT evidence) | Moderate (European evidence) | Very low (Feb–Nov season) | Moderate symptom control |
| 5-yr cost | $3,500–$15,000 | $1,500–$4,500 | Minimal | $500–$3,000/5 yrs |
| Duration | 3–5 years | 3–5 years | Lifelong | Lifelong use |
| Convenience | At-home self-injection; weekly build-up then monthly | Daily at home | High daily disruption | Daily medication burden |
| Safety | Excellent; Virtual Shot Room–supervised dosing + prescribed epi | Very high — no injection risk | Excellent | Generally safe |
| Lasting effect | Yes — 7–12+ yrs | Emerging evidence | No | No |
At-Home SCIT (Curex)Best
SLIT drops/tablets
Avoidance
Medications
For patients with genuine Par j 2 sensitization confirmed by component testing, SCIT offers the only treatment with documented lasting immunological modification. Curex now delivers that subcutaneous immunotherapy as an at-home allergy shot with pricing confirmed in a current program quote: a Par j 2-guided Parietaria serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, a prescribed epinephrine auto-injector confirmed on hand, and week-by-week dose escalation overseen by a board-certified allergist — so eligible patients get the durable-modification modality without weekly clinic trips.
What Pellitory SCIT Actually Costs
Most major US insurers cover allergen immunotherapy when prescribed by a board-certified allergist; Parietaria extract is non-standardized in the US, so formulary coverage may vary. Patients in California coastal practices should verify pellitory extract availability under their plan. Curex at-home IgE testing identifies specific pellitory sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your pellitory allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Pellitory SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Pellitory (Parietaria judaica and P. officinalis) is a small perennial plant in the nettle family that grows in wall cracks, ruins, and urban margins across the Mediterranean basin and coastal California. It is the dominant cause of pollinosis in populations of Sicily, Naples, and coastal Spain — affecting up to 80% of pollinosis patients in those regions — but has historically been underrecognized in US clinical practice because most US allergists trained in ragweed-dominated regions. As Parietaria expands along the California coast and mid-Atlantic ports, more US allergists are incorporating Par j 2 component testing into their panels.
Pellitory allergy diagnosis in the US typically begins with a skin prick test using a non-standardized Parietaria extract (ImmunoCAP w21). However, because pellitory sensitization frequently co-exists with pan-allergen reactivity from profilin and polcalcin, a skin prick test alone cannot confirm genuine species-specific sensitization. Component-resolved diagnostics — specifically serum-specific IgE to Par j 2 (the marker for genuine Mediterranean-type Parietaria sensitization) — are the gold standard. In one study, Par j 2 reactivity was found in 83% of Mediterranean patients but only 7% of non-Mediterranean patients with apparent Parietaria sensitization, illustrating why component testing matters.
Most patients notice meaningful improvement in rhinitis and conjunctivitis symptoms during the first full pollen season after reaching the maintenance dose — typically 6–12 months after initiating SCIT. In the Italian RCT evidence base (Frati et al. 2006), statistically significant symptom score improvements were demonstrated by year 1 of maintenance. Full immunological modification with lasting benefit beyond the treatment period generally requires completing the full 3–5 year course. Patients initiating pre-seasonally in November benefit from reaching maintenance before the February pollen onset.
No — pellitory and stinging nettle are different plants in the same family (Urticaceae), with very different allergen profiles. Stinging nettle (Urtica dioica) is known mostly for its sting from hollow trichomes that inject histamine, acetylcholine, and other compounds — this is a universal irritant reaction, not IgE-mediated allergy. Nettle pollen is a minor aeroallergen with minimal published clinical evidence. Pellitory (Parietaria), by contrast, has the well-characterized Par j 1 and Par j 2 major allergens, robust SCIT RCT data from Italy, and causes severe pollinosis in Mediterranean populations. Par j 1 and Par j 2 LTPs are NOT present in Urtica, confirming the two are clinically distinct.
Yes — antihistamines can be taken during pellitory SCIT, but timing matters. Antihistamines taken immediately before an injection may mask early signs of a systemic reaction, which is why some allergists recommend holding antihistamines for 24 hours prior to each injection visit. During the pollen season between injections, antihistamines are an appropriate adjunct to SCIT — the goal is layered symptom control while immunotherapy builds tolerance. Your allergist will provide specific guidance on antihistamine timing based on your reaction history during the build-up phase.
Pellitory sensitization is associated with asthma in Mediterranean populations, and Italian SCIT evidence suggests that allergen immunotherapy can reduce lower-airway hyperreactivity alongside rhinitis improvement. The European EAACI position on allergen immunotherapy and asthma (Roberts et al. 2018) supports SCIT as a disease-modifying treatment that may prevent development of new asthma in rhinitis patients and reduce asthma severity in those already affected. Patients with active asthma should have FEV1 measured before each injection during the build-up phase, as active bronchospasm increases systemic reaction risk. On the reassurance side, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically reported with office-based shots.
Pellitory is primarily established in coastal Southern California and the San Francisco Bay area, where the Mediterranean-type climate supports its February–November pollen season. Scattered populations are documented at mid-Atlantic and Gulf Coast port cities — the plant likely arrived via shipping ballast and ornamental trade. Climate projections suggest continued US range expansion as warming winters create more favorable overwintering conditions. Allergists in Florida, Texas, and mid-Atlantic states are increasingly seeing patients with Parietaria sensitization, so the geographic footprint is growing.
European evidence supports both SCIT and SLIT for Parietaria allergy — Italian guidelines often recommend SLIT drops as a first-line option because of the long pollen season and need for near-year-round treatment. In the US, sublingual drops are used off-label and are not FDA-approved for pellitory. Head-to-head comparisons specifically for Parietaria are limited, but EAACI meta-analyses suggest SLIT achieves roughly 70–80% of SCIT efficacy for many allergens, with a substantially better safety profile due to elimination of injection risk. The appropriate choice depends on symptom severity, adherence profile, and component-test results confirming genuine sensitization.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.